High Signal Podcasts Evidence ledger
Method
Browse
← Back to evidence

Evidence receipt / belief

Published · transcript-backed

Jonathan Frankle: belief

20 May 2023 Latent Space MPT-7B and The Beginning of Context=Infinity — with Jonathan Frankle and Abhinav Venigalla of MosaicML

“I think I'm, I'm still in my heart, the second year grad student who was jealous of all his friends who had GPUs and he didn't, and I couldn't train any models except in my laptop.”

— Jonathan Frankle

Source trail

Everything needed to verify it.

Speaker
Jonathan Frankle
Attribution
Verified speaker
Claim type
belief
Recorded
20 May 2023
Publisher
Latent Space

Transcript context

…Do you think a lot of the questions that we have around, you know, what data sets we should use and things like that are just because training was so expensive before that, we just haven't run enough experiments to figure that out. And is that one of your goals is trying to make it cheaper so that we can actually get the answers? Yeah, that's a big part of my personal conviction for being here. I think I'm, I'm still in my heart, the second year grad student who was jealous of all his friends who had GPUs and he didn't, and I couldn't train any models except in my laptop. And that, I mean, the lottery ticket experiments began on my laptop that I had to beg for one K 80 so that I could run amist. And I'm still that person deep down in my heart. And I'm a believer that, you know, if we wanna do science and really understand these systems and understand how to make them work well, understand how they behave, understand what makes them safe and reliable. We need to make it cheap enough that we can actually do science, and science involves running dozens of experiments. When I finally, you know, cleaned out my g c s bucket from my PhD, I deleted a million model checkpoints. I'm not kidding. There were over a million model checkpoints. That is the kind of science we need, you know, that's just what it takes. In the same way that if you're in a biology lab, you don't just grow one cell and say like, eh, the drug seems to work on that cell. Like, there's a lot more science you have to do before you really know. Yeah. And I think one of the special things about Mosaic's kind of [00:37:30] position as well is that we have such, so many customers all trying to train models that basically we have the incentive to like to devote all these resources and time to do this science. Because when we learn which pieces actually work, which ones don't, we get to help many, many people, right? And so that kind of aggregation process I think is really important for us. I remember way back there was a paper about Google that basically would investigate batch sizes or something like that. And it was this paper that must have cost a few million dollars during all the experience. And it was just like, wow, what a, what a benefit to the whole community. Now, like now we all get to learn from that and we get, we get to save. We don't have to spend those millions of dollars anymore. So I think, um, kind of mosaical science, like the insights we get on, on data, on pre-screening architecture, on all these different things, um, that's why customers come to us.…

Stored transcript either side of the excerpt. The highlighted words are the published quote; the surrounding text is unedited source, never generated.

Search evidence